Third Rock Partner Mark Levin is excited about emerging science, but somewhat pessimistic about the environment for companies pursuing it.
Partner and co-founder of early stage life science venture firm Third Rock Ventures Mark Levin told the audience at a May 15 Manhattan Institute conference on The Digital Future of Molecular Medicine that he was excited about the emerging science but he sees a system-wide failure to fund and nurture innovative early-stage companies.
Levin's voice is one to be reckoned with. Over the past 38 years, he's worked as a project manager at...
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.
